Posted by Michael Wonder on 07 Apr 2022
TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (Xevudy) for the BA.2 omicron sublineage
7 April 2022 - The TGA has received an application from GSK for a higher (1,000 mg) dose of its COVID-19 treatment, sotrovimab (Xevudy).
This higher dose will be considered for treatment of patients suspected to have infection caused by the omicron BA.2 sublineage.
